BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• 

  Duchenne muscular dystrophy

  Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era

  While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.

  January 27, 2025

   · 

  8 min read

   · 

  Kate Goodwin
• 

  Duchenne muscular dystrophy

  5 DMD Candidates to Watch in 2025

  Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and more aim to deliver the next wave of progress with near-term data and regulatory milestones.

  January 27, 2025

   · 

  6 min read

   · 

  Kate Goodwin
• 

  Opinion

  Competition for Achondroplasia Treatments Heats Up Slowly

  Achondroplasia, which affects around one in 20,000 babies, has just one approved treatment: BioMarin’s Voxzogo. However, new investigational treatments are vying to compete in the area.

  January 27, 2025

   · 

  4 min read

   · 

  Jia Jie Chen
• 

  Cancer

  BMS, Pfizer Challenge Colorectal Cancer Standard Care With ASCO GI Readouts

  Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of metastatic colorectal cancer.

  January 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Biogen, Eisai Win Nod for Monthly Leqembi Maintenance Amid Stagnant Sales

  The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for patients with Alzheimer’s, could help with Leqembi’s thus far disappointing uptake and sales.

  January 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Weight loss

  Veru’s Drug Spares Lean Mass in Overweight, Obese Adults on Wegovy—Is It Enough?

  Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy alone but investors await more data.

  January 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Akero Rebounds as Benefit Deepens in Key Mid-Stage MASH Trial

  After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed greater improvements after 96 weeks of treatment in an advanced disease population.

  January 27, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Legal

  Pfizer Settles Biohaven Kickback Suit for Nearly $60M

  From March 2020 through September 2022, Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.

  January 27, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives

  Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

  January 27, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  Allakos Will Axe 75% of Workforce, Drop Hives Candidate

  Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.

  January 27, 2025

   · 

  1 min read

   · 

  Angela Gabriel